IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 3089 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (3,215 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References
   Article Figures
   Article Tables

 Article Access Statistics
    Viewed363    
    Printed5    
    Emailed0    
    PDF Downloaded17    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR - OBSERVATION LETTER
Year : 2019  |  Volume : 85  |  Issue : 1  |  Page : 97-100

Eruptive squamous cell carcinomas associated with programmed cell death protein-1 inhibitor therapy


Department of Dermatology, University of Virginia Health System, Charlottesville, VA, USA

Date of Web Publication11-Dec-2018

Correspondence Address:
Dr. Jack Lee
Department of Dermatology, University of Virginia Health System, PO Box 800718, Charlottesville, VA 22908
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijdvl.IJDVL_147_18

Rights and Permissions



How to cite this article:
Lee J, Guffey DJ, Noland MMB, Russell MA. Eruptive squamous cell carcinomas associated with programmed cell death protein-1 inhibitor therapy. Indian J Dermatol Venereol Leprol 2019;85:97-100

How to cite this URL:
Lee J, Guffey DJ, Noland MMB, Russell MA. Eruptive squamous cell carcinomas associated with programmed cell death protein-1 inhibitor therapy. Indian J Dermatol Venereol Leprol [serial online] 2019 [cited 2019 Mar 26];85:97-100. Available from: http://www.ijdvl.com/text.asp?2019/85/1/97/247314




Sir,

We would like to present a case of eruptive squamous cell carcinomas (SCC) associated with programmed cell death protein 1 (PD-1) inhibitors and propose topical corticosteroids as a possible first-line therapy. PD-1 inhibitors are immunotherapy agents used to treat metastatic melanoma and other malignancies. They inhibit homeostatic checks on the immune system and amplify T-cell-mediated tumor surveillance.[1] The immune activation is nonspecific and can cause autoimmune sequelae and dermatologic adverse events.[1] Nine cases have been reported in the literature describing a potential new dermatologic adverse event, the development of eruptive skin neoplasms months following treatment with PD-1 inhibitors. Eight developed eruptive keratoacanthomas[2],[3],[4],[5],[6] and one developed a mixed eruption of two keratoacanthomas/one actinic keratosis/two basal cell carcinomas/one SCC.[4] We have not found any prior reports associating PD-1 inhibitor use with eruptive SCC.

Our patient was an 83-year-old male with metastatic melanoma. He was initially treated with intravenous nivolumab 240 mg every 14 days for six doses. Though the patient completed this regimen in 10 weeks, he had not achieved an adequate response as determined by imaging, and was planned for four additional doses of combination therapy with ipilimumab (3 mg/kg) and nivolumab (1 mg/kg). The first dose of combination therapy was initiated 12 weeks following his first dose of nivolumab monotherapy. Four days later, he developed a morbilliform rash covering his upper body, mostly affecting his upper chest and upper arms and sparing the dorsal hands. There were no constitutional symptoms, derangements in renal or liver function or elevated eosinophil counts. Due to the degree of body surface area affected, immunotherapy was discontinued and an oral prednisone taper was started at 50 mg daily, tapering by 5 mg every 3 days. The rash quickly resolved. However, around the time when the taper reached 10 mg, numerous hyperkeratotic papules and nodules suddenly erupted over his extensor forearms and dorsal hands [Figure 1]. At this point it had been about 4 months since he received his first dose of nivolumab. Initially, four representative lesions were sampled and histopathology revealed atypical squamous proliferations with variable-sized islands of keratinocytes with increased nuclear-to-cytoplasm ratios and a scattered dermal lichenoid infiltrate composed largely of lymphocytes, which was consistent with invasive well-differentiated SCC [Figure 2]a,[Figure 2]b,[Figure 2]c. The prednisone taper was completed, and his new lesions were treated with triamcinolone 0.1% ointment to be applied twice daily. After two months the lesions resolved completely except for two remaining nodules [Figure 3]. The nodules were biopsied and curetted, with histopathology again consistent with invasive well-differentiated SCC. Curetted sites were healing well at 2-week and 1-month follow-ups with no signs of recurrence. Immunotherapy was never restarted after his first dose of combination therapy as his metastatic lesions remained stable or improved since the onset of his adverse events.
Figure 1: Numerous erythematous hyperkeratotic papules and nodules abruptly appeared bilaterally over the dorsal forearms and hands about 4 months after initiating PD-1 inhibitor therapy (arrows/outlines).

Click here to view
Figure 2: Magnification (a) ×12.5 (b) ×40 (c) ×100. Biopsy of representative hyperkeratotic nodule from the right dorsal hand showing atypical squamous proliferations with variable sized islands of keratinocytes with increased nuclear to cytoplasm ratios and a scattered dermal lichenoid infiltrate composed largely of lymphocytes, consistent with invasive well differentiated squamous cell carcinoma (hematoxylin and eosin).

Click here to view
Figure 3: After treatment with triamcinolone 0.1% ointment twice daily for 2 months. Erythema improved and lesions decreased in size and number, with only two residual nodules remaining (arrows).

Click here to view


Besides our patient, nine patients have been cited to develop eruptive skin neoplasms after using PD-1 inhibitors (clinical features summarized in [Table 1]). Eight developed eruptive keratoacanthomas[2],[3],[4],[5],[6] and one developed a mixed eruption of two keratoacanthomas/one actinic keratosis/two basal cell carcinomas/one SCC.[4] Naranjo score was 7, indicating probable causality. Eruptive SCC is a well-known adverse event of B-Rapidly Accelerated Fibrosarcoma (BRAF) inhibitors, but not with PD-1 inhibitors.[7] To our knowledge, our case represents the first report of PD-1 inhibitor-associated eruptive SCC.
Table 1: Characteristics of patients developing eruptive skin neoplasms following programed cell death protein 1 inhibitor use

Click here to view


In our eruptive SCC case and the nine cases of other eruptive skin neoplasms cited in the literature, lesions occurred in sun-exposed areas of the trunk and extremities, curiously sparing the head and neck in all except the case featuring the mixed eruption. Among the nine cases cited in the literature, the median latency period from starting PD-1 inhibitors to first appearance of eruptive skin neoplasms ranged from 2 to 18 months. The latency period of our patient also falls within this range, at 4 months. Our patient had been taking ipilimumab (CTLA-4 inhibitor) concurrently with nivolumab for 1 week prior to the onset of his eruptive SCC and one of the patients cited in the literature was started on cabiralizumab (CSF1R inhibitor) concurrently with nivolumab.[5] However, we agree with Feldstein et al. that it is unlikely that ipilimumab or cabiralizumab contributed to eruptive skin neoplasms, as the eight other patients were on PD-1 inhibitors alone.[5] Additionally, eruptive skin neoplasms have not been previously reported with either ipilimumab or cabiralizumab.[5]

Eight of the nine cases from the literature showed good response to treatment. One patient improved on topical and intralesional 5-FU[3] and one improved on imiquimod.[5] Two saw complete resolution with destructive methods alone with no recurrence or new lesions at follow-up,[4],[5] and one resolved spontaneously without intervention.[4] All five of these patients had PD-1 inhibitors discontinued. However, the patient treated with 5-FU continued to develop new lesions. Freites-Martinez et al. reported the three remaining patients, the only patients in whom PD-1 inhibitors were continued.[2] Lesions in these three completely resolved with topical and/or intralesional corticosteroids alone or in combination with cryotherapy.[2] For our patient, PD-1 inhibitors were discontinued and the lesions almost completely resolved with topical corticosteroids alone. The excellent response to corticosteroids in our patient as well as that of the three patients of Freites-Martinez et al. is interesting to note.[2]

Eruptive skin neoplasms associated with PD-1 inhibitors have been postulated to arise primarily due to increased inflammation.[2],[3],[5],[6] PD-1 inhibitor use causes an increase in inflammatory cytokines, which can act as growth factors for sub-clinically damaged keratinocytes already predisposed to proliferate irregularly. Feldstein et al. compared this phenomenon to keratoacanthomatous proliferations arising in lichenoid dermatitis such as verrucous lupus erythematosus or hypertrophic lichen planus.[5] Interestingly, in all five eruptive skin neoplasm cases from the literature that commented on histology, a lichenoid infiltrate was found on biopsy. Our patient's biopsies also demonstrated lichenoid infiltrates.

This “inflammatory hypothesis” is consistent with the observation that when topical and intralesional corticosteroids are used, the eruptive skin neoplasms recede, presumably because the inflammation and therefore the primary proliferative stimulus is neutralized. Skin neoplasms arising under normal circumstances would be expected to worsen in the setting of immunosuppressive agents such as corticosteroids. However, the eruptive skin neoplasms associated with PD-1 inhibitors may be a distinct entity, perhaps a less advanced form of skin neoplasm that is unable to undergo full malignant transformation without a sustained outside stimulus, such as the inflammatory milieu caused by PD-1 inhibitors.

Induction of immune-related dermatologic adverse events, particularly vitiligo, morbilliform rash, lichenoid dermatitis, or pruritus is associated with improved responses to PD-1 inhibition.[2],[8] Eruptive skin neoplasms might similarly serve as a favorable prognostic indicator for the original malignancy that the PD-1 inhibitor was indicated for, as they were seen in the setting of a known immune-related dermatologic adverse event in six of the nine eruptive skin neoplasm cases from the literature. Our patient also developed a morbilliform rash that was likely due to immunotherapy given the morphology, lack of other triggering agents in the patient's history, and its resolution following discontinuation of immunotherapy. However, it is unclear whether nivolumab or combination therapy triggered it. Four of the eruptive skin neoplasm cases from the literature commented on outcomes for the primary malignancy and three completely responded while one had stabilized metastases. Our eruptive SCC patient also responded well, with stabilized or improved metastases.

Eruptive skin neoplasms, including eruptive SCC, are a potential new immune-related dermatologic adverse event associated with the use of PD-1 inhibitors. Treatment with destructive methods may be impractical due to the sheer number of lesions. We propose that topical corticosteroids be considered a potential first-line treatment option for these lesions given the number of responders in the literature and the overall favorable side-effect profile of this therapy. Intralesional corticosteroids and destructive modalities can also be considered for isolated lesions that prove recalcitrant to topical therapy. Prognosis is favorable and the lesions themselves may portend a good prognosis for the original malignancy.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the journal. The patient understands that name and initials will not be published and due effort will be made to conceal identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Lee JJ, Kroshinsky D, Hoang MP. Cutaneous reactions to targeted therapy. Am J Dermatopathol 2017;39:67-82.  Back to cited text no. 1
    
2.
Freites-Martinez A, Kwong BY, Rieger KE, Coit DG, Colevas AD, Lacouture ME. Eruptive keratoacanthomas associated with pembrolizumab therapy. JAMA Dermatol 2017;153:694-7.  Back to cited text no. 2
    
3.
Chaudhari S, Leon A, Levin E, Neuhaus I, Liao W. Case report of multiple keratoacanthomas and squamous cell carcinomas in a patient receiving pembrolizumab. J Drugs Dermatol 2017;16:513-5.  Back to cited text no. 3
    
4.
Bandino JP, Perry DM, Clarke CE, Marchell RM, Elston DM. Two cases of anti-programmed cell death 1-associated bullous pemphigoid-like disease and eruptive keratoacanthomas featuring combined histopathology. J Eur Acad Dermatol Venereol 2017;31:e378-80.  Back to cited text no. 4
    
5.
Feldstein SI, Patel F, Larsen L, Kim E, Hwang S, Fung MA. Eruptive keratoacanthomas arising in the setting of lichenoid toxicity after programmed cell death 1 inhibition with nivolumab. J Eur Acad Dermatol Venereol 2018;32:e58-9.  Back to cited text no. 5
    
6.
Bandino JP, Elston DM. Response to ‘Eruptive keratoacanthomas arising in the setting of lichenoid toxicity after patients on antiprogrammed cell death-1 inhibition with nivolumab’. J Eur Acad Dermatol Venereol2018;32:e61-2.  Back to cited text no. 6
    
7.
Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol 2015;72:221-36.  Back to cited text no. 7
    
8.
Hwang SJ, Anforth R, Carlos G, Wakade D, Byth K, Kong BY, et al. Cutaneous adverse events of new anti-melanoma therapies: Classification and management. Actas Dermosifiliogr 2017;108:6-16.  Back to cited text no. 8
    


    Figures

  [Figure 1], [Figure 2], [Figure 3]
 
 
    Tables

  [Table 1]



 

Top
Print this article  Email this article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow